Imatinib treatments have long-term impact on placentation and embryo survival

Wael Salem, Kailiang Li, Christopher Krapp, Sue Ann Ingles, Marisa S. Bartolomei, Karine Chung, Richard J. Paulson, Romana Angelika Nowak, Lynda K. McGinnis

Research output: Contribution to journalArticle

Abstract

Imatinib is an oral chemotherapeutic used primarily to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). The potential effects of cancer treatments on a patient’s future fertility are a major concern affecting the quality of life for cancer survivors. The effects of imatinib on future fertility are unknown. It is teratogenic. Therefore, patients are advised to stop treatment before pregnancy. Unfortunately, CML and GIST have high rates of recurrence in the absence of the drug, therefore halting imatinib during pregnancy endangers the mother. Possible long-term (post-treatment) effects of imatinib on reproduction have not been studied. We have used a mouse model to examine the effects of imatinib on the placenta and implantation after long-term imatinib exposure. We found significant changes in epigenetic markers of key imprinted genes in the placenta. There was a significant decrease in the labyrinth zone and vasculature of the placenta, which could impact fetal growth later in pregnancy. These effects on placental growth occurred even when imatinib was stopped prior to pregnancy. These results indicate potential long-term effects of imatinib on pregnancy and implantation. A prolonged wash-out period prior to pregnancy or extra monitoring for possible placental insufficiency may be advisable.

Original languageEnglish (US)
Article number2535
JournalScientific reports
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Placentation
Embryonic Structures
Survival
Pregnancy
Placenta
Gastrointestinal Stromal Tumors
Therapeutics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Fertility
Placental Insufficiency
Imatinib Mesylate
Inner Ear
Fetal Development
Epigenomics
Reproduction
Survivors
Neoplasms
Mothers
Quality of Life
Recurrence

ASJC Scopus subject areas

  • General

Cite this

Salem, W., Li, K., Krapp, C., Ingles, S. A., Bartolomei, M. S., Chung, K., ... McGinnis, L. K. (2019). Imatinib treatments have long-term impact on placentation and embryo survival. Scientific reports, 9(1), [2535]. https://doi.org/10.1038/s41598-019-39134-0

Imatinib treatments have long-term impact on placentation and embryo survival. / Salem, Wael; Li, Kailiang; Krapp, Christopher; Ingles, Sue Ann; Bartolomei, Marisa S.; Chung, Karine; Paulson, Richard J.; Nowak, Romana Angelika; McGinnis, Lynda K.

In: Scientific reports, Vol. 9, No. 1, 2535, 01.12.2019.

Research output: Contribution to journalArticle

Salem, W, Li, K, Krapp, C, Ingles, SA, Bartolomei, MS, Chung, K, Paulson, RJ, Nowak, RA & McGinnis, LK 2019, 'Imatinib treatments have long-term impact on placentation and embryo survival', Scientific reports, vol. 9, no. 1, 2535. https://doi.org/10.1038/s41598-019-39134-0
Salem W, Li K, Krapp C, Ingles SA, Bartolomei MS, Chung K et al. Imatinib treatments have long-term impact on placentation and embryo survival. Scientific reports. 2019 Dec 1;9(1). 2535. https://doi.org/10.1038/s41598-019-39134-0
Salem, Wael ; Li, Kailiang ; Krapp, Christopher ; Ingles, Sue Ann ; Bartolomei, Marisa S. ; Chung, Karine ; Paulson, Richard J. ; Nowak, Romana Angelika ; McGinnis, Lynda K. / Imatinib treatments have long-term impact on placentation and embryo survival. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{163561b4170144029fd08d4b27d9e274,
title = "Imatinib treatments have long-term impact on placentation and embryo survival",
abstract = "Imatinib is an oral chemotherapeutic used primarily to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). The potential effects of cancer treatments on a patient’s future fertility are a major concern affecting the quality of life for cancer survivors. The effects of imatinib on future fertility are unknown. It is teratogenic. Therefore, patients are advised to stop treatment before pregnancy. Unfortunately, CML and GIST have high rates of recurrence in the absence of the drug, therefore halting imatinib during pregnancy endangers the mother. Possible long-term (post-treatment) effects of imatinib on reproduction have not been studied. We have used a mouse model to examine the effects of imatinib on the placenta and implantation after long-term imatinib exposure. We found significant changes in epigenetic markers of key imprinted genes in the placenta. There was a significant decrease in the labyrinth zone and vasculature of the placenta, which could impact fetal growth later in pregnancy. These effects on placental growth occurred even when imatinib was stopped prior to pregnancy. These results indicate potential long-term effects of imatinib on pregnancy and implantation. A prolonged wash-out period prior to pregnancy or extra monitoring for possible placental insufficiency may be advisable.",
author = "Wael Salem and Kailiang Li and Christopher Krapp and Ingles, {Sue Ann} and Bartolomei, {Marisa S.} and Karine Chung and Paulson, {Richard J.} and Nowak, {Romana Angelika} and McGinnis, {Lynda K.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-39134-0",
language = "English (US)",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Imatinib treatments have long-term impact on placentation and embryo survival

AU - Salem, Wael

AU - Li, Kailiang

AU - Krapp, Christopher

AU - Ingles, Sue Ann

AU - Bartolomei, Marisa S.

AU - Chung, Karine

AU - Paulson, Richard J.

AU - Nowak, Romana Angelika

AU - McGinnis, Lynda K.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Imatinib is an oral chemotherapeutic used primarily to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). The potential effects of cancer treatments on a patient’s future fertility are a major concern affecting the quality of life for cancer survivors. The effects of imatinib on future fertility are unknown. It is teratogenic. Therefore, patients are advised to stop treatment before pregnancy. Unfortunately, CML and GIST have high rates of recurrence in the absence of the drug, therefore halting imatinib during pregnancy endangers the mother. Possible long-term (post-treatment) effects of imatinib on reproduction have not been studied. We have used a mouse model to examine the effects of imatinib on the placenta and implantation after long-term imatinib exposure. We found significant changes in epigenetic markers of key imprinted genes in the placenta. There was a significant decrease in the labyrinth zone and vasculature of the placenta, which could impact fetal growth later in pregnancy. These effects on placental growth occurred even when imatinib was stopped prior to pregnancy. These results indicate potential long-term effects of imatinib on pregnancy and implantation. A prolonged wash-out period prior to pregnancy or extra monitoring for possible placental insufficiency may be advisable.

AB - Imatinib is an oral chemotherapeutic used primarily to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). The potential effects of cancer treatments on a patient’s future fertility are a major concern affecting the quality of life for cancer survivors. The effects of imatinib on future fertility are unknown. It is teratogenic. Therefore, patients are advised to stop treatment before pregnancy. Unfortunately, CML and GIST have high rates of recurrence in the absence of the drug, therefore halting imatinib during pregnancy endangers the mother. Possible long-term (post-treatment) effects of imatinib on reproduction have not been studied. We have used a mouse model to examine the effects of imatinib on the placenta and implantation after long-term imatinib exposure. We found significant changes in epigenetic markers of key imprinted genes in the placenta. There was a significant decrease in the labyrinth zone and vasculature of the placenta, which could impact fetal growth later in pregnancy. These effects on placental growth occurred even when imatinib was stopped prior to pregnancy. These results indicate potential long-term effects of imatinib on pregnancy and implantation. A prolonged wash-out period prior to pregnancy or extra monitoring for possible placental insufficiency may be advisable.

UR - http://www.scopus.com/inward/record.url?scp=85062027672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062027672&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-39134-0

DO - 10.1038/s41598-019-39134-0

M3 - Article

C2 - 30796277

AN - SCOPUS:85062027672

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 2535

ER -